Literature DB >> 10576553

Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720.

Y Hozumi1, E Kobayashi, M Miyata, A Fujimura.   

Abstract

While autoimmune disease needs to be continuously treated via long term, administration of immunosuppressants conventional immunotherapy using drugs such as cyclosporin and tacrolimus may cause adverse effects. Recently, a novel agent, FTY720, which was structurally modified from a natural product, has been shown to have a moderate and different immunosuppressive effect from conventional drugs. In this study, we examined the effect of FTY720 on experimental autoimmune thyroiditis (EAT), which was induced in rats by neonatal thymectomy, followed by subsequent sublethal irradiation. Thyroid stimulating hormone (TSH) was measured before and at the end of drug therapy. Histological and hematological examinations were performed using the samples from sacrificed animals. High TSH levels in the animals returned to the normal range following treatment with FTY720. The severity of the thyroiditis was lower in the FTY720 group than in the control group. FTY720 markedly decreased the number of circulatory lymphocytes, and no infections episodes were observed under this treatment. Thus, FTY720 treatment might be preferred for continuous immunotherapy for autoimmune disease without adverse effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576553     DOI: 10.1016/s0024-3205(99)00426-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

Review 1.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  Effect of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice.

Authors:  Jing-Hua He; Hui-Na Zhang; Zhi-Bin Lin
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

Review 3.  [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].

Authors:  J Klatt; H-P Hartung; R Hohlfeld
Journal:  Nervenarzt       Date:  2007-10       Impact factor: 1.214

4.  Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro.

Authors:  P J Zhou; H Wang; G H Shi; X H Wang; Z J Shen; D Xu
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.